News & Updates
Filter by Specialty:
Ticagrelor monotherapy following short-term DAPT more suitable for seniors with ACS
For older acute coronary syndrome (ACS) patients with implanted bioabsorbable polymer sirolimus-eluting stents, a strategy involving ticagrelor monotherapy after 3‐month dual antiplatelet therapy (DAPT) is better than ticagrelor‐based 12‐month DAPT, according to a post hoc analysis of the TICO* trial. Furthermore, the beneficial effect of ticagrelor monotherapy increases with age and is strongest among patients aged ≥64 years.
Ticagrelor monotherapy following short-term DAPT more suitable for seniors with ACS
25 Dec 2021Sintilimab-IBI305-chemo improves PFS in EGFRm non-squamous NSCLC
The combination of the anti-PD-1 monoclonal antibody sintilimab with the bevacizumab biosimilar IBI305 and pemetrexed and cisplatin chemotherapy improved progression-free survival (PFS) in patients with EGFR*-mutated (EGFRm) non-squamous non-small-cell lung cancer (NSCLC), according to interim analysis results of the phase III ORIENT-31 trial from China.
Sintilimab-IBI305-chemo improves PFS in EGFRm non-squamous NSCLC
24 Dec 2021Statin adherence a must to reduce stroke risk among hyperlipidemia patients
Patients with hyperlipidemia who take their statin medication as prescribed appear to do well, with treatment adherence conferring significant protection against the risk of ischaemic and haemorrhagic strokes, as reported in a study.
Statin adherence a must to reduce stroke risk among hyperlipidemia patients
24 Dec 2021Repeat surgery plus chemo may improve survival in recurrent ovarian cancer
The DESKTOP* III trial has shown that patients whose ovarian cancer recurs have better overall survival (OS) following secondary cytoreductive surgery plus platinum-based chemotherapy compared with a platinum-based chemotherapy regimen alone.
Repeat surgery plus chemo may improve survival in recurrent ovarian cancer
23 Dec 2021Aumolertinib a win in EGFR T790M-positive advanced NSCLC
The novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) aumolertinib appears to be effective in the treatment of patients with EGFR T790M-positive advanced nonsmall cell lung carcinoma (NSCLC) following progression on first- and second-generation EGFR TKI therapy, according to data from the phase II APOLLO Registrational Trial.